Core Viewpoint - Hong Kong Pharma Digital Technology Holdings Limited (HKPD) successfully passed all proposals at its 2025 annual meeting, indicating a strategic shift and governance updates for the company [1][2][3]. Group 1: Shareholder Proposals - Proposal No. 1 involved the re-election of five directors to serve until the 2026 Annual Meeting [1]. - Proposal No. 2 ratified the appointment of Onestop Assurance PAC as the independent registered public accounting firm for the fiscal year ending March 31, 2026 [1]. - Proposal No. 3 increased the authorized share capital from US$100,000 to US$1,000,000, allowing for a total of 1,000,000,000 ordinary shares [1]. Group 2: Share Structure Changes - Proposal No. 4 re-designated and re-classified the company's shares into Class A and Class B ordinary shares [2]. - Proposal No. 5 approved a Reverse Share Split and Share Consolidation of the company's issued and outstanding ordinary shares [2]. Group 3: Corporate Identity and Governance - Proposal No. 6 changed the company's name to "Cellyan Biotechnology Co., Ltd" and its foreign name to "生研生物公司" [3]. - Proposal No. 7 adopted the fourth amended and restated memorandum and articles of association [3]. - Proposal No. 8 involved the repurchase of 7,150,000 Class A Ordinary Shares and the issuance of Class B Ordinary Shares [3]. - Proposal No. 9 approved the 2025 Equity Incentive Plan [3]. Group 4: Company Overview - HKPD specializes in OTC pharmaceutical cross-border e-commerce supply chain services through its subsidiary, Joint Cross Border Logistics Company Limited [4]. - The company also engages in OTC pharmaceutical cross-border procurement and distribution via its subsidiary, V-Alliance Technology Supplies Limited [4]. - Joint Cross Border provides a comprehensive service offering, including product procurement, logistics, and delivery for Mainland Chinese customers seeking OTC pharmaceutical products [5][6].
Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders